Chromatin Bioscience Signs Collaboration Agreement with Astellas
EDINBURGH, Scotland, April 14, 2025 /PRNewswire/ -- Chromatin Bioscience, a leader in the design of synthetic promoters and gene control systems, is pleased to announce a collaboration agreement with Astellas Pharma, a global life sciences company.
Under the agreement, Chromatin Bioscience will use its proprietary chromatinLENS platform to design cell-selective synthetic promoters aligned with Astellas' target profile. The designed promoters are expected to enable highly precise and durable gene expression in specific cell types.
"We're excited to begin this collaboration with Astellas," said Michael Roberts, CEO and Founder of Chromatin Bioscience. "We believe the ability to precisely control targeted gene expression is becoming increasingly critical across diverse applications in biotechnology. This collaboration reflects the growing interest in synthetic promoter technology as a key enabler in the development of precision-targeted biological systems."
Chromatin Bioscience's chromatinLENS platform enables the identification of gene regulatory elements from the dark genome and the rational design of synthetic promoters tailored to specific applications. The platform can be applied across a range of sectors—including therapeutics, agritech, industrial biotechnology, and bioprocessing. The collaboration with Astellas further validates the potential of the chromatinLENS platform and represents the latest milestone in a series of collaborations that are shaping Chromatin's continued growth and impact.
For more information about Chromatin Bio's recent collaborations, visit https://www.chromatinbio.com/news
Notes to Editors
About Chromatin Bioscience
Chromatin Bioscience is a biotechnology company focused on the design and development of synthetic promoters for targeted gene control systems. Its proprietary platform enables precise, cell-type-selective, and durable gene expression, which is key to advancing the next generation of therapeutics, bioproduction systems and agritech innovations. Chromatin's synthetic promoters have been integral to a growing number of client programs. For more information, visit www.chromatinbio.com.
PR Newswire Asia Ltd.
PR Newswire
1954年に設立された世界初の米国広報通信社です。配信ネットワークで全世界をカバーしています。Cision Ltd.の子会社として、Cisionクラウドベースコミュニケーション製品、世界最大のマルチチャネル、多文化コンテンツ普及ネットワークと包括的なワークフローツールおよびプラットフォームを組み合わせることで、様々な組織のストーリーを支えています。www.prnasia.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
プレスリリース添付画像
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
